NCNA has been granted a new patent
Jun 26, 2024, 10:38 PM
27.53%
What does NCNA do
NuCana Plc, a clinical stage biopharmaceutical company, leverages its ProTide technology to enhance cancer treatment, with key drugs like NUC-3373 and NUC-7738 currently in clinical trials. NUC-3373 targets advanced colorectal cancer, while NUC-7738, a transformation of 3’-deoxyadenosine, is being tested in patients with advanced solid tumors.
NCNA filed a patent for "synthesis of phosphate derivatives" on Mon, August 15, 2022. The patent was officially published on Thu, December 22, 2022.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.